BlueCrest Capital Management’s ProKidney PROK Stock Holding History

BlueCrest Capital Management’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-125,000	Closed	-$1.24M	–	233
2022 Q1	$1.24M	Buy	125,000 +5,619	+5%	+$55.4K	0.04%	183
2021 Q4	$1.18M	Sell	119,381 -505,619	-81%	-$5M	0.04%	221
2021 Q3	$6.13M	Sell	625,000 -125,000	-17%	-$1.23M	0.17%	111
2021 Q2	$7.58M	Buy	+750,000	New	+$7.58M	0.14%	146

Other funds holding PROK

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $200M AUM 23.6% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

BlueCrest Capital Management's PROK Position: Q2 2022 in Review

BlueCrest Capital Management sold out of ProKidney (PROK) in Q2 2022, closing a stake of 125,000 shares — an estimated $1.24M sold.

BlueCrest Capital Management first reported a position in PROK in Q2 2021 and held it in 4 quarters. The position peaked at $7.58M in Q2 2021. 67 funds tracked by Wall St. Rank hold PROK as of Q2 2022.

BlueCrest Capital Management reported no remaining ProKidney position as of Q2 2022 after selling out during the quarter.
BlueCrest Capital Management sold 125,000 ProKidney shares in Q2 2022, an estimated $1.24M.
BlueCrest Capital Management first reported a position in ProKidney in Q2 2021 and held it in 4 quarters.
BlueCrest Capital Management's ProKidney position peaked at $7.58M in Q2 2021.
67 funds tracked by Wall St. Rank held ProKidney as of Q2 2022.

Based on BlueCrest Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.